Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs
Frontiers in Public Health · 2026
DOI: 10.3389/fpubh.2026.1822376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Marco Schito und 9 weiteren Autor:innen. Beteiligte Einrichtung: CURE Drug Repurposing Collaboratory, Critical Path Institute, Tucson, AZ, United States. Hauptthemen laut MEDLINE: Drug Repositioning, Clinical Trials as Topic, COVID-19 Drug Treatment. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FDA HHS.
Abstract (Originalsprache)
Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CURE Drug Repurposing Collaboratory, Critical Path Institute, Tucson, AZ, United States.
- Myalgic Encephalomyelitis Action Network, Santa Monica, CA, United States.
- Stanford University School of Medicine, Stanford, CA, United States.
- Patient Led Research Collaborative, New York, NY, United States.
- Global Cures, Inc., Newton, MA, United States.
- Emory University School of Medicine, Atlanta, GA, United States.
Förderung
- FDA HHS
Zitieren
APA
Schito, M., Coe, S., Seltzer, J., Davis, H. E., Sukhatme, V., Johnson Ii, T. W., Stone, J., Truong, A. D., Geng, L. N., & Walker, T. A. (2026). Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1822376
Vancouver
Schito M, Coe S, Seltzer J, Davis HE, Sukhatme V, Johnson Ii TW, et al. Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1822376
BibTeX
@article{Schito2026,
author = {Schito, Marco and Coe, Stacey and Seltzer, Jaime and Davis, Hannah E and Sukhatme, Vidula and Johnson Ii, Theodore W and Stone, Judy and Truong, Alexander D and Geng, Linda N and Walker, Tiffany A},
title = {Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs},
journal = {Frontiers in Public Health},
year = {2026},
doi = {10.3389/fpubh.2026.1822376}
}
EUVIMED